Loading
Respiratory Viral Infections Research · Journal article
Vaccines · September 2, 2026
A consensus or society position rather than new primary data.
This consensus document recommends integrated early infancy RSV prevention combining maternal vaccination and infant monoclonal antibodies as complementary rather than competing strategies. Maternal vaccination provides protection from birth when administered sufficiently before delivery; direct infant monoclonal antibody prophylaxis offers rapid protection independent of maternal response. Strategy selection should be individualized based on gestational age, vaccination-to-delivery interval, infant risk, RSV seasonality, and local implementation feasibility rather than assuming universal superiority of either approach.
Consensus Development Group using modified Delphi process. Infants at risk of RSV lower respiratory tract disease in early infancy; pregnant women for maternal immunization; focus on implementation across diverse settings and equity considerations.. Intervention: Maternal RSV immunization (RSVpreF vaccine) and long-acting infant monoclonal antibodies as integrated prevention strategies.. Compared with: Maternal RSV vaccination versus infant monoclonal antibody prophylaxis within coordinated prevention pathway; comparison contingent on clinical context rather than assumed universal superiority..
Maternal vaccination protects from birth when administered sufficiently before delivery Direct infant monoclonal antibody prophylaxis provides rapid protection independent of maternal immune response and placental transfer Post-pandemic disruption of RSV seasonality increases importance of flexible prevention strategies protecting infants born outside historically defined seasonal windows
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians and public health officials should position maternal RSV vaccination and infant monoclonal antibodies as complementary strategies within a coordinated pathway rather than competing approaches. Implementation decisions should account for local RSV epidemiology, antenatal care access, product availability, cost, and individual infant risk factors including prematurity and delivery timing.
A multidisciplinary consensus document using modified Delphi process to integrate evidence on maternal RSV immunization and infant monoclonal antibodies into coordinated prevention strategy recommendations.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians and public health officials should position maternal RSV vaccination and infant monoclonal antibodies as complementary strategies within a coordinated pathway rather than competing approaches. Implementation decisions should account for local RSV epidemiology, antenatal care access, product availability, cost, and individual infant risk factors including prematurity and delivery timing.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease and hospitalization in early infancy. The availability of maternal RSVpreF vaccination and long-acting infant monoclonal antibodies has created two effective but operationally distinct pathways for passive protection. Methods: This WAidid consensus document focuses on maternal RSV immunization within an integrated early infancy prevention strategy. A multidisciplinary Consensus Development Group reviewed evidence on infant RSV burden and seasonality, maternal vaccine efficacy and effectiveness, transplacental antibody transfer, long-acting monoclonal antibodies, implementation, equity, and economic considerations. Recommendations were developed using a modified Delphi process with a prespecified consensus threshold of at least 75% agreement. Results: Maternal vaccination can provide protection from birth when administered sufficiently before delivery, whereas direct infant monoclonal antibody prophylaxis provides rapid protection independent of maternal immune response and placental transfer. The relative value of the two approaches depends on gestational age, vaccination-to-delivery interval, infant risk, birth timing, local RSV circulation, antenatal care access, product availability, and cost. Post-pandemic disruption of RSV seasonality increases the importance of flexible strategies that protect infants born outside historically defined seasonal windows. Direct head-to-head evidence remains limited; therefore, policy decisions should integrate trial efficacy, emerging real-world effectiveness, implementation feasibility, and local epidemiology rather than assume universal superiority of one strategy. Conclusions: Maternal vaccination and infant monoclonal antibodies should be positioned within a coordinated prevention pathway. Maternal vaccination may serve as the principal strategy for appropriately timed pregnancies with reliable antenatal access, while infant monoclonal antibodies are particularly important when maternal vaccination is absent, too close to delivery, or potentially ineffective, or when the infant is preterm or otherwise at increased risk. Surveillance and locally adapted implementation are essential to maintain protection as RSV epidemiology evolves.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.